Recent developments for Jaguar Health include analyst coverage initiation with a buy recommendation, strategic import announcements related to its biosciences joint venture, participation in investor conference calls, and increased market interest as indicated by search activity.

• First Berlin initiated coverage of Jaguar Health with a buy recommendation in May 2025, indicating analyst interest in the company [N2].
• Jaguar Health announced the import of coca leaf by its Magdalena Biosciences joint venture in December 2024, reflecting operational progress [N3].
• The company participated in a conference call with Ladenburg Thalmann in December 2024, engaging with investors and analysts [N4].
• Jaguar Health was mentioned in a biotech alert highlighting spiking search interest in April 2026, suggesting increased market attention [N1].

Jaguar Health has established FDA approval and commercialization of Mytesi for HIV/AIDS-related diarrhea and conditional approval of Canalevia-CA1 for canine inflammatory diarrhea, supported by a licensing agreement with Woodward Specialty LLC. The company is expanding its product pipeline with Gelclair and NP-300, targeting additional gastrointestinal conditions. Its focused research and development efforts, combined with strategic partnerships and a specialized botanical drug platform, provide potential for growth in niche markets. Recent news coverage includes positive analyst initiation and strategic import activities, indicating market interest and operational progress.

Jaguar Health faces significant financial challenges, including recurring net losses, a stockholders' deficit, and liquidity constraints with a current ratio of 0.5 and limited cash reserves. The company is substantially dependent on a single customer, Woodward Specialty LLC, for revenue, creating concentration risk. Regulatory approvals for follow-on indications and new products remain uncertain. Supply chain dependencies on two raw material suppliers and third-party manufacturers pose risks of disruption. The company also faces intense competition from larger pharmaceutical firms and risks related to Nasdaq listing compliance. These factors, combined with the need for substantial additional capital, create material risks to business continuity and growth.

Jaguar Health's moat is primarily based on its proprietary botanical drug crofelemer, used in its lead products Mytesi and Canalevia-CA1, and its patent portfolio including formulation and method-of-use patents. The company has exclusive licensing agreements with Woodward Specialty LLC for commercialization in the U.S. Its focus on rare disease programs and niche gastrointestinal health markets provides some differentiation. However, the botanical nature of its active ingredient and method-of-use patents may not fully prevent competitors from developing similar products for other uses. Dependence on limited suppliers and contract manufacturers also presents operational risks that could affect competitive positioning.

• Limited Operating History and Profitability: Jaguar Health has a limited operating history and has incurred significant losses, with net comprehensive losses of $54.4 million in 2025. The company expects to continue incurring losses as it expands product development and commercialization activities, which may affect its ability to sustain operations.
• Dependence on Single Customer: The company's future revenue is substantially dependent on Woodward Specialty LLC under a manufacturing and supply agreement. This concentration risk could materially impact revenue if the relationship or commercialization efforts are unsuccessful.
• Regulatory Approval and Commercialization Risks: Obtaining regulatory approvals for current and future products is uncertain. Even with approvals, market acceptance is not guaranteed, and delays or failures could adversely affect financial results.
• Supply Chain Dependencies: Jaguar Health relies on two suppliers for the key raw material crofelemer and third-party contract manufacturers for production. Termination or disruption of these contracts could harm product development and commercialization.
• Liquidity and Capital Requirements: The company has limited cash resources and a current ratio of 0.5 as of December 31, 2025. It faces substantial capital needs for ongoing operations, clinical trials, and commercialization, with risks of being unable to raise funds on acceptable terms.
• Nasdaq Listing Risks: Failure to meet Nasdaq continued listing requirements, including minimum stockholders' equity and bid price, could result in delisting, reducing liquidity and access to capital markets.
• Competition: Jaguar Health competes with major pharmaceutical companies in the gastrointestinal health market, which may affect its ability to commercialize products successfully.
• Royalty and Debt Obligations: The company has royalty interests and secured promissory notes with minimum payments starting in July 2026, which may strain cash resources and affect financial flexibility.

• Jaguar Health, Inc. is a pharmaceutical company focused on human and animal health prescription drugs, headquartered in San Francisco, California, with additional offices for Jaguar Animal Health.
• The company completed the acquisition of Napo Pharmaceuticals Inc. in 2017, which is a key part of its operations.
• Jaguar Health's lead prescription drug product is Mytesi, approved by the FDA for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
• The company also commercializes Canalevia-CA1, a conditionally approved prescription drug for chronic inflammatory diarrhea (CID) in dogs, launched in December 2021.
• Jaguar Health has a license agreement with Woodward Specialty LLC (an affiliate of Future Pak, LLC) granting Woodward exclusive rights to commercialize Mytesi and Canalevia products in the United States, effective January 12, 2026.
• The company is developing additional products including NP-300 and Gelclair, the latter being a prescription treatment for oral mucositis in cancer patients.
• As of December 31, 2025, Jaguar Health had 47 employees, including 9 with advanced degrees (M.D., D.V.M., Ph.D.), with 17 in research and development and 18 in sales and marketing.
• The company leases approximately 10,998 rentable square feet of office space in San Francisco.
• Financial figures as of December 31, 2025, include revenue of $11.5 million, net loss of $53.6 million, and basic and diluted EPS of -$22.97 per share.
• Cash and cash equivalents were $968,000, current assets $20.3 million, and current liabilities $40.7 million, resulting in a current ratio of 0.5 and a cash ratio of 0.02 as of December 31, 2025.
• Jaguar Health has a total stockholder's deficit of $18.7 million as of December 31, 2025, and there is substantial doubt about its ability to continue as a going concern beyond March 2027 without additional financing.
• The company expects to incur significant additional costs related to research, development, clinical trials, regulatory approvals, and commercialization efforts, particularly focusing on rare disease programs.
• Jaguar Health is substantially dependent on the success of Woodward Specialty LLC for commercialization of Mytesi and Canalevia-CA1, with future revenue streams primarily from this single customer under a manufacturing and supply agreement.
• The company faces competition in the gastrointestinal pharmaceutical space from major companies such as Takeda Pharmaceuticals and Ironwood Pharmaceuticals, among others.
• Jaguar Health depends on two suppliers for the raw material (crofelemer from Croton lechleri tree) used in its active pharmaceutical ingredients, and on third-party contract manufacturers for production and supply of finished products.
• The company has issued royalty interests and secured promissory notes with outstanding balances around $30 million as of April 7, 2026, with minimum royalty payments starting July 2026, which may strain cash resources.
• Jaguar Health has recently amended royalty interest agreements to postpone royalty payments and reduce repayment amounts by 10%.
• The company faces risks related to limited operating history, ongoing losses, need for substantial additional capital, regulatory approval uncertainties, supplier dependencies, competition, and potential delisting risks from Nasdaq.
• Recent news includes initiation of coverage with a buy recommendation by First Berlin in May 2025, announcement of import of coca leaf by Magdalena Biosciences JV in December 2024, participation in a conference call with Ladenburg Thalmann in December 2024, and mention in a biotech alert for spiking searches in April 2026.